These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 21563089

  • 1. The role of ultrahigh-frequency audiometry in the early detection of systemic drug-induced hearing loss.
    Singh Chauhan R, Saxena RK, Varshey S.
    Ear Nose Throat J; 2011 May; 90(5):218-22. PubMed ID: 21563089
    [Abstract] [Full Text] [Related]

  • 2. High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity.
    Fausti SA, Henry JA, Schaffer HI, Olson DJ, Frey RH, McDonald WJ.
    J Infect Dis; 1992 Jun; 165(6):1026-32. PubMed ID: 1583319
    [Abstract] [Full Text] [Related]

  • 3. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
    Reavis KM, Phillips DS, Fausti SA, Gordon JS, Helt WJ, Wilmington D, Bratt GW, Konrad-Martin D.
    Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
    [Abstract] [Full Text] [Related]

  • 4. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer.
    Caballero M, Mackers P, Reig O, Buxo E, Navarrete P, Blanch JL, Grau JJ.
    Oncology; 2017 Dec; 93(2):75-82. PubMed ID: 28511189
    [Abstract] [Full Text] [Related]

  • 5. [The "Muenster classification" of high frequency hearing loss following cisplatin chemotherapy].
    Schmidt CM, Bartholomäus E, Deuster D, Heinecke A, Dinnesen AG.
    HNO; 2007 Apr; 55(4):299-306. PubMed ID: 16437215
    [Abstract] [Full Text] [Related]

  • 6. COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.
    Crabb SJ, Martin K, Abab J, Ratcliffe I, Thornton R, Lineton B, Ellis M, Moody R, Stanton L, Galanopoulou A, Maishman T, Geldart T, Bayne M, Davies J, Lamb C, Popat S, Joffe JK, Nutting C, Chester J, Hartley A, Thomas G, Ottensmeier C, Huddart R, King E.
    Eur J Cancer; 2017 Dec; 87():75-83. PubMed ID: 29128692
    [Abstract] [Full Text] [Related]

  • 7. Ototoxicity in Nigeria: why it persists.
    Kokong DD, Bakari A, Ahmad BM.
    Ear Nose Throat J; 2014 Jul; 93(7):256-64. PubMed ID: 25025411
    [Abstract] [Full Text] [Related]

  • 8. The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy.
    Abujamra AL, Escosteguy JR, Dall'Igna C, Manica D, Cigana LF, Coradini P, Brunetto A, Gregianin LJ.
    Pediatr Blood Cancer; 2013 Mar; 60(3):474-8. PubMed ID: 22744939
    [Abstract] [Full Text] [Related]

  • 9. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives.
    van der Hulst RJ, Dreschler WA, Urbanus NA.
    Ann Otol Rhinol Laryngol; 1988 Mar; 97(2 Pt 1):133-7. PubMed ID: 3281541
    [Abstract] [Full Text] [Related]

  • 10. The role of antioxidants in protection from ototoxic drugs.
    Sergi B, Fetoni AR, Ferraresi A, Troiani D, Azzena GB, Paludetti G, Maurizi M.
    Acta Otolaryngol Suppl; 2004 May; (552):42-5. PubMed ID: 15219046
    [Abstract] [Full Text] [Related]

  • 11. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
    Biró K.
    Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
    [Abstract] [Full Text] [Related]

  • 12. High-frequency audiometric monitoring strategies for early detection of ototoxicity.
    Fausti SA, Larson VD, Noffsinger D, Wilson RH, Phillips DS, Fowler CG.
    Ear Hear; 1994 Jun; 15(3):232-9. PubMed ID: 8076721
    [Abstract] [Full Text] [Related]

  • 13. The importance of audiometric monitoring in patients with multidrug-resistant tuberculosis.
    Vasconcelos KA, Frota SMMC, Ruffino-Netto A, Kritski AL.
    Rev Soc Bras Med Trop; 2017 Jun; 50(5):646-651. PubMed ID: 29160511
    [Abstract] [Full Text] [Related]

  • 14. The importance of high-tone audiometry in monitoring for ototoxicity.
    Tange RA, Dreschler WA, van der Hulst RJ.
    Arch Otorhinolaryngol; 1985 Jun; 242(1):77-81. PubMed ID: 3899068
    [Abstract] [Full Text] [Related]

  • 15. Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system.
    Stöhr W, Langer T, Kremers A, Bielack S, Lamprecht-Dinnesen A, Frey E, Beck JD, German Late Effects Working Group in the German Society of Pediatric Oncology and Hematology.
    Cancer Invest; 2005 Jun; 23(3):201-7. PubMed ID: 15945505
    [Abstract] [Full Text] [Related]

  • 16. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
    Knight KR, Kraemer DF, Winter C, Neuwelt EA.
    J Clin Oncol; 2007 Apr 01; 25(10):1190-5. PubMed ID: 17401008
    [Abstract] [Full Text] [Related]

  • 17. Applications of the Grading Scales for the Detection of Ototoxicity in Children after Treatment of Neuroblastoma and Extracranial Germinal Tumor.
    Polski B, Sosnowska-Sienkiewicz P, Szydłowski J, Januszkiewicz-Lewandowska D.
    Audiol Neurootol; 2023 Apr 01; 28(1):32-42. PubMed ID: 36191558
    [Abstract] [Full Text] [Related]

  • 18. Ototoxicity monitoring with ultra-high frequency audiometry in peritoneal dialysis patients treated with vancomycin or gentamicin.
    van der Hulst RJ, Boeschoten EW, Nielsen FW, Struijk DG, Dreschler WD, Tange RA.
    ORL J Otorhinolaryngol Relat Spec; 1991 Apr 01; 53(1):19-22. PubMed ID: 2008289
    [Abstract] [Full Text] [Related]

  • 19. Early ototoxic changes in patients with germ cell tumor after first cycle of cisplatin-based therapy.
    Noszek L, Budai B, Prekopp P, Széchenyi R, Szőnyi M, Talpai S, Nagyiványi K, Bíró K, Géczi L.
    Laryngoscope; 2017 Aug 01; 127(8):E277-E282. PubMed ID: 27666741
    [Abstract] [Full Text] [Related]

  • 20. [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
    Biró K, Noszek L, Prekopp P, Nagyiványi K, Géczi L, Gaudi I, Bodrogi I.
    Magy Onkol; 2006 Aug 01; 50(4):329-35. PubMed ID: 17216007
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.